Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both

医学 泌尿科 欧洲联盟 尿 肾 基线(sea) 临床试验 还原(数学) 内科学 泌尿系统 药品 肾脏疾病 急性肾损伤 梅德林
作者
Amy K. Mottl,Charlie Scott,Jennifer B. Green,Hiddo J.L. Heerspink,Johannes F.E. Mann,Janet B. McGill,Masaomi Nangaku,Julio Rosenstock,Peter Rossing,Li Li,Na Li,Muthiah Vaduganathan,Rajiv Agarwal,on behalf of the CONFIDENCE Trial Investigators
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:37 (4): 764-776 被引量:2
标识
DOI:10.1681/asn.0000000928
摘要

KEY POINTS: We assessed whether baseline urine albumin-creatinine ratio (UACR) and eGFR modify treatment effects on UACR reduction and safety in the CONFIDENCE trial. Higher baseline eGFR or UACR, age, female sex, and atherosclerotic cardiovascular disease were associated with greater albuminuria lowering at 6 months (180 days). Treatment effects on efficacy and safety were consistent, with no significant heterogeneity across baseline UACR or eGFR groups. BACKGROUND: In the CONFIDENCE trial, simultaneous initiation of finerenone (10 or 20 mg) and empagliflozin (10 mg) was superior to either monotherapy in reducing albuminuria at 180 days in participants with type 2 diabetes and CKD. In this analysis, we evaluated whether baseline urine albumin-creatinine ratio (UACR) and eGFR were associated with the magnitude of UACR reduction, and whether baseline UACR and eGFR modify the effect of combination treatment. METHODS: In this post hoc analysis of the CONFIDENCE trial ( n =796), linear mixed-effects models were used to evaluate the effects of baseline UACR and eGFR on the change in UACR from baseline using subgroups on the basis of clinically relevant thresholds of UACR (<300 versus ≥300 mg/g) and eGFR (<60 versus ≥60 ml/min per 1.73 m 2 ). Logistic regression models were used to assess the odds of achieving UACR reductions at day 180. RESULTS: At day 180, higher baseline eGFR (per 10 ml/min per 1.73 m 2 ) was independently associated with a -7% (95% confidence interval [CI], -11 to -4) greater reduction in UACR ( P < 0.001), and higher baseline UACR (per log change of UACR) was independently associated with a -9% (95% CI, -14 to -3) greater reduction in UACR ( P < 0.001). However, the treatment effect of finerenone, empagliflozin, or their combination on changes in UACR levels was not modified by baseline levels of eGFR or UACR. Besides the use of combination therapy, independent predictors of >30% reduction in UACR were age (odds ratio [OR], 1.23 per 10 years [95% CI, 1.05 to 1.45]), female sex (OR, 1.95 [95% CI, 1.32 to 2.86]), and atherosclerotic cardiovascular disease (OR, 1.63 [95% CI, 1.13 to 2.35]). The safety end points showed no significant heterogeneity across UACR or eGFR. CONCLUSIONS: Overall, greater albuminuria lowering was seen with a higher baseline eGFR or UACR, older age, in female patients, and those with atherosclerotic cardiovascular disease, irrespective of the treatment. Albuminuria-lowering with combination therapy, finerenone, or empagliflozin treatment effects were independent of baseline eGFR or UACR. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT05254002 ; European Union Drug Regulating Authorities Clinical Trials Database 2021-003037-11 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
冷酷画板完成签到,获得积分20
2秒前
月亮喜欢吃月饼完成签到 ,获得积分10
2秒前
忧郁的汉堡完成签到,获得积分10
2秒前
强小强努力努力完成签到,获得积分10
2秒前
Lyuoah完成签到,获得积分10
2秒前
4秒前
4秒前
稀西发布了新的文献求助10
5秒前
675675发布了新的文献求助30
5秒前
6秒前
Maestro_S的应助被achilles采纳,获得10
6秒前
乐乐的应助被achilles采纳,获得10
6秒前
阿申爱乐的应助被正直迎夏采纳,获得30
7秒前
ccccc完成签到 ,获得积分10
8秒前
科研通AI65的应助被Lighter采纳,获得10
8秒前
科研通AI6.3的应助被小艾同学采纳,获得10
9秒前
yummy完成签到 ,获得积分10
11秒前
11秒前
啦啦啦完成签到,获得积分10
12秒前
14秒前
乌龙茶发布了新的文献求助10
18秒前
molihuakai的应助被fengfengfeng采纳,获得10
18秒前
18秒前
空白格完成签到 ,获得积分10
19秒前
sun完成签到,获得积分10
20秒前
20秒前
yeo发布了新的文献求助10
20秒前
Coco完成签到,获得积分10
21秒前
22秒前
cc发布了新的文献求助20
23秒前
23秒前
23秒前
落叶完成签到,获得积分10
24秒前
正直迎夏给正直迎夏的求助进行了留言
25秒前
易宋发布了新的文献求助30
25秒前
26秒前
大模型的应助被小贾没有投篮采纳,获得10
26秒前
26秒前
111完成签到,获得积分20
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181767
求助须知:如何正确求助?哪些是违规求助? 9571480
关于积分的说明 21818225
捐赠科研通 7778030
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479598